GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Monday, May 4, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 72

Author

Pharma Journalist 8769 posts 0 comments

Illumina & Ovation.io Launch Novel GLP-1 Dataset for Faster Therapy Development

May 6, 2025
Illumina and Ovation.io have announced a groundbreaking collaboration to create the largest commercially available clinical multiomic dataset from 25,000 patients treated with GLP-1…
Read More...

FDA Approves Johnson & Johnson’s IMAAVY for Broad Generalized Myasthenia Gravis…

May 5, 2025
Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu), a novel human monoclonal antibody that blocks the neonatal…
Read More...

Creyon Bio and Lilly Partner on RNA-Targeted Oligo Therapy

Apr 30, 2025
Creyon Bio, Inc. announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of…
Read More...

QIAGEN Expands Digital PCR Portfolio with New Lentivirus Solutions

Apr 30, 2025
QIAGEN announced the expansion of its cell and gene therapy (CGT) portfolio with enhanced digital PCR (dPCR) solutions tailored for lentivirus-based applications. These solutions are…
Read More...

FDA Approves RINVOQ for Giant Cell Arteritis

Apr 30, 2025
AbbVie announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This…
Read More...

Oxford, Boehringer, Cumulus Launch First-Ever Study on Daily Life with Psychiatric Disorders

Apr 30, 2025
Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric…
Read More...

FDA Approves ZEVASKYN, First Cell-Based Gene Therapy for RDEB

Apr 29, 2025
Abeona Therapeutics Inc. announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel) gene-modified cellular…
Read More...

Merck Breaks Ground on $1B Biologics Center in Delaware

Apr 29, 2025
Merck, known as MSD outside the U.S. and Canada, has announced the start of construction on a $1 billion, 470,000-square-foot Biologics Center of Excellence in Wilmington, Delaware.…
Read More...

Prilenia Partners with Ferrer for Pridopidine in Europe and Beyond

Apr 28, 2025
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease…
Read More...

Biohaven Secures Up to $600M Investment from Oberland Capital

Apr 28, 2025
Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.